Trial Profile
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Rosmantuzumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors OncoMed Pharmaceuticals
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 09 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2018.
- 04 Jan 2018 According to an OncoMed Pharmaceuticals media release, data from the trial ill be presented at a future medical conference.